TTNP - Earnings call 3 2020 | Titan Pharmaceuticals, Inc.

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Thank you for holding, and welcome to the Titan Pharmaceuticals Third Quarter 2020 Financial Results Conference Call. Please be advised that this call is being taped at the company's request and will be archived on the company's website starting later today.

At this time, I would like to turn the call over to Dr. Marc Rubin, Executive Chairman of Titan Pharmaceuticals. Please go ahead.

Marc Rubin

Sarah. you, Thank thank us always, all you of And you joining today. for as to the Quarter Welcome Pharmaceuticals Titan to Third XXXX Call. Conference

and at our begin, release press we provides website we XX-Q on September I to the quarterly and filed with inform Form found report the XXXX, and our issued summary earlier ending third Before operational quarter SEC, can on results of be you the www.titanpharm.com. want a also have the that financial today XX, for

me and Titan our Joining call Dr. is from on today Chief the Kate DeVarney, President Officer. Operating

know, Bhonsle for opportunity many, his years. to Titan would all like you best unwavering thank made We As we retirement. from many contributions all this take his Sunil many, to the retire decision and the to the to And very, over him recently him company. well-earned wish the very for has dedication

oversee product and Kate company's development the forward, activities. I Moving will

has in our The prior of Titan stage development to relevance from is company. operating diminished, a a commercial that transitioned results back

discussing -- rather attention who I'd your review Kiernan, draw filings. to cautions rather the required forward-looking statements. call this regarding discussing the aforementioned the to I'll to like And will today, Jennifer Jennifer? now than turn So

Jennifer Kiernan

meaning Section XXXX are everyone financial of stock Act and Section Marc. our could I of statements than and the any the affect our want business, that to, not statements that to forward-looking XXA programs certain commercialization price. are Thank Act negatively operating other product you, and will of limited of not statements Securities and statements Such to that uncertainties of development discussed and results, contain Securities that involve historical facts. within XXXX. but statements conditions any include, Such risks today remind other relating the be matters historical XXE may Exchange information

ability strategic and regulatory process; any revisions any or to cause forward-looking U.S. related to any change to risks uncertainties or down to reflect production winding raise circumstances or or current management's and testing, our of conditions could Probuphine; development, expressly relating undertaking our of statements expectations and is except based, obligation required capital; differ any disclaim in commercial marketing publicly our to approval matters; actual updates the which contained agreements events, by and any candidates; release changes the that We include herein drug those relationships. law. on to property such the statement Factors results patent and any as in expectations intellectual activities materially from to

now to I'll turn Marc. you, the call over back

Marc Rubin

stockholders update XX. to of assets, Thanks, completed a for Jennifer. meeting overview our ago on JT-XX a and public and weeks key have brief And we'd a and like nalmefene. of call X today's We focus offering November X scheduled

details of developments the So Titan filed all recently the are via disclosures with at SEC. available recent of a number

give this who one will JT call stage company, Our of assets, means from the briefly costs. represents on for in being And nalmefene. Pharma. agonist a is acquired we I kappa a we in that that the expertise. have which overview key recent recently by begin JT-XX, result and core to to Kate, operating really restructuring receptor which Titan back growth over brief a of peptide development opioid aims position fixed our describing is expected reductions It will before company is future substantial to go program also to our X turning to

of this of pain. animal with looking chronic and using had in pruritus, chronic focus we several on looking feasibility kidney to initially work based pruritus work through was we end-stage initially treating potential chronic a we the models. ProNeura at years the patients peptide-infused on assess JT-XX JT-XX ago that of focused acquisition explore treatment actually of for feasibility to in the pivoted for The began have the disease. delivering implants providing at for But recently, treatment JT-XX nonaddictive implants And

varying, number conditions. lotions, very skin X condition, over-the-counter weeks, pruritus debilitating relatively that million itself. many defined undesirable chronic by based ineffective. itching is pruritus longer Chronic cutaneous antihistamines, to estimated of than the treatments effect And Americans from of are for of of chronic systemic as lasts general and million for number XX as include suffer well the a current on pruritus etiology in of side of which And pruritus all caused corticosteroids, a profiles, have the course, XX an as a

is in humans The itch opioid immune disease. peripheral end-stage liver opioid neurons. kappa chronic antipruritic small application demonstrated opioid Toray's to chronic a kidney first in pruritus of nalfurafine The was to nalfurafine. kappa receptors Toray for kappa binding and kappa definitively their Industries in by agonist effect keratinocytes, related and pruritus efficacy cells for agonist of of thought a be to disease highly treatment approved using called potent agonist in Japan the molecule for on was

have about disease. patients end-stage affect who does of Pruritus XX% kidney

central pruritus is been CNS-related and Japan. adverse sleep, only system, the for events small actually depression that there of is with increased and nalfurafine is observed. very some nervous associated prevalent, poor in chronic overall it of molecule it's mortality. approved Because a Nalfurafine life, So quality have very into treatment penetrates Toray's poor the

Cara plans has Phase selective of the application And call pruritus a in Therapeutics U.S. in new in in agonist recently, a efficacy CRXXX, second they with submit receptor More III of peptide, XXXX. associated the kappa undergoing the Phase end-stage in disease drug the of opioid announced to treatment half dialysis. it both Cara clinical demonstrated and kidney trials patients II

levels subcutaneous therapeutic of of nonfluctuating period or multiple in-office of We long the on our a based This longer ProNeura potentially rods months deliver early could data, eliminate medication weekly single animal delivering could procedure. implementation that following JT-XX believe JT need concentrations by potentially for a over time. X therapeutic injections of relatively for

conducting peptide, safety establishing this JT-XX get drug the plan we investigational new towards pharmacology quarter are and studies. of and of We successful, to expect If data we enabling working on XXXX. proof-of-concept the second in then now proof-of-concept

will we course, data our updated it. keep and on Of key as we generate progress share you

like call discuss Kate? pass to who's nalmefene would to development the now program. I to our Kate, going

Kate Glassman Beebe

Thank you, Marc.

know, XXXX we a opioid including are for injectable depression. of the of As nalmefene based implant reversal for detoxification. you respiratory and of developing nalmefene following part is of the overdose, management FDA's prevention formulation an program This on relapse opioid in approval

was In in Agency by Medicines alcohol XXXX treating the addition, oral nalmefene European dependence. approved for

filing years grant IND. the development, for Abuse, grant XXXX, studies Drug this Institute and In NIDA, approximately over awarded The NIDA an funds for completion program. of manufacturing GMP on X September implant required or us the provides of nonclinical $X.X National million the for formulation

We NIDA the milestone, the which of first is the are half in next regarding filing and in communication with program, remain we XXXX. progress our meet this IND on of to regular track

the which Now will the approximately by for allow is the $X.X remaining to of FDA million. acceptance of IND apply grant, the portion us to NIDA

the nalmefene formulation. We to be from required lack due The have should guidance to FDA advised FDA approval on a follow long-acting and the will file data clear safety regulatory received the the nonclinical the on for pathway, IND. that of product XXX(b)(X) also that's that studies this

to input, collect that's chronic ongoing well approved all accepted study the conduct increase based to on plan data funds of reallocate conduct previously an required. toxicology and this So has duration studies. to additional nonclinical the plan we an study our as to NIDA as these

near has of progress. potential So both our in programs forward on that refocused by and our next toward long-term We're and milestones ProNeura-based working both our we our to the in summary, ProNeura the of achieving believe of new on year you platform middle opportunities. strategy value-generating corporate look updating development

call. all participating this on for Thank you

really support, continued your we our Thank forward to you. and forward. As ProNeura appreciate portfolio we ongoing always, look move progress in as we reporting

Operator

you for has today's The attending conference Thank now presentation. concluded.

You may disconnect. now

Titan Pharmaceuticals (TTNP) 16 Nov 202020 Q3 Earnings call transcript